TPO and Cirrhosis: TPO-RAs (including eltrombopag or romiplostim) are another novel platelet-elevating drugs that bind to and activate the thrombopoietin (TPO) receptor, induce megakaryocyte progenitor proliferation by JAK2/STAT5 pathway, and finally increase PCs in chronic thrombocytopenia induced by immune, HCV infection or cirrhosis [36–38].